Ultra Long-Acting Insulin for Type 1 Diabetes

Overview
Ultra long-acting insulin is a type of insulin therapy used to manage blood glucose (sugar) levels in individuals with type 1 diabetes. Types of insulin approved by the U.S. Food and Drug Administration (FDA) that are considered ultra long-acting include insulin degludec (Tresiba) and insulin glargine U-300 (Toujeo).

It is designed to provide a stable level of insulin to manage blood glucose (sugar) levels and reduce the risk of hypoglycemia (low blood sugar), especially during the night​​​​. Ultra long-acting insulin reaches the bloodstream within six hours and remains active for as long as 42 hours.

How do I take it?
Ultra long-acting insulin is administered through subcutaneous (under the skin) injections. It is typically injected once daily, preferably at the same time each day, to maintain consistent blood glucose levels. It’s important to rotate injection sites to prevent lipodystrophy (changes in fat tissue). Follow your health care provider’s guidance for proper injection technique and dosing.

Side effects
Common side effects of ultra long-acting insulin can include hypoglycemia, allergic reactions at the injection site, changes in vision, and weight gain. Long-term use of insulin, including ultra long-acting insulin, can lead to changes in fat tissue at the injection site.

Severe side effects may include severe hypoglycemic episodes​​​​.

For more details about this treatment, visit:

Side Effects of Long-Acting Insulin — NHS
https://www.nhs.uk/medicines/insulin/long-actin...

What Is the Best Long-Acting Insulin? A Review of Tresiba and Other Brands — GoodRx Health
https://www.goodrx.com/tresiba/is-tresiba-the-b...